News

As per terms of the merger deal, Promedior will secure an upfront cash payment of $390m, as well as additional contingent payments of up to $1bn based on

This is the first acceptance of a regulatory submission for an oral MEK 1/2 monotherapy for patients with NF1, a rare and incurable genetic condition. A Prescription Drug

The purpose of this funding round, which will be split into three tranches, is to progress the late-stage clinical development of EpicentRx’s lead anticancer agent, RRx-001, and proprietary

Fetroja has been approved for patients 18 years of age or older who have limited or no alternative treatment options to treat cUTI, including pyelonephritis. It can be

The late-stage study evaluated subcutaneously administered mepolizumab 300mg (3x100mg) every four weeks against placebo in 108 adolescent and adult patients with severe HES. The HES trial met its

Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohn’s disease, a form of inflammatory bowel disease. Finch’s Human-First Discovery platform

Closing of the transaction is anticipated to occur after the consummation of the proposed merger of RDD and Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT) which will form a combined

The transaction includes an upfront payment and contingent milestone payments. Calporta is involved in the development of selective small-molecule agonists to TRPML1 (transient receptor potential cation channel, mucolipin

Founded in 1998, Unison is an independent private equity firm investing in the healthcare sector across Japan, Korea and Singapore, with an emphasis on the pharmaceutical sector. Unison